Atlas Venture, Bain Capital Life Sciences and RTW Investments led a $400m Series A round in Kailera Therapeutics.

Atlas Venture, Bain Capital Life Sciences and RTW Investments led a $400m Series A round in Kailera Therapeutics, a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, with participation from Lyra Capital. "In this period of rapid innovation in the metabolic space, I believe that Kailera is poised to make an impact beyond the current market leaders. We have an incredible opportunity to develop next-generation treatments for chronic weight management, helping people reclaim their health and live their lives to the fullest," Ron Renaud, Kailera Therapeutics CEO.